RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - May 15, 2008) - Adherex Technologies Inc. (TSX: AHX) (AMEX: ADH), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today that the results of a preclinical study of ADH-1 in combination with chemotherapy were published in the May issue of Cancer Research. The study, entitled “Targeting N-Cadherin Enhances Antitumor Activity of Cytotoxic Therapies in Melanoma Treatment,"(1) was conducted by Dr. Douglas Tyler and colleagues at the Duke Comprehensive Cancer Center.
